Choosing the best first biologic for moderate to severe colitis
Part of Digestive system clinical trials.
This study compares two first-line biologic drugs for moderate to severe ulcerative colitis to see which works better and why. The goal is to help find the best biologic treatment for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with moderate to severe ulcerative colitis by your doctor.
- You are not taking any other treatments that could interfere with the study drugs or surgery for ulcerative colitis during the follow-up period.
- You do not have serious liver or kidney problems, active infections (like hepatitis, TB, HIV), or cancer in the digestive tract.
- You are not allergic to the study drugs (infliximab or vedolizumab).
- You are not pregnant, breastfeeding, or planning to get pregnant during the study.
- You are able to come for regular check-ups and blood tests as required.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three different types of biologic medications to find which works best as a first treatment for moderate-to-severe ulcerative colitis.
This trial compares how well different combinations of drugs calm inflammation in the gut compared to single drugs. It uses tissue samples taken during a colonoscopy to see which approach works best for people with inflammatory bowel disease.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
This trial compares different biologic medications (adalimumab, infliximab, ustekinumab, or vedolizumab) to see how well they work after one year in people with moderate-to-severe ulcerative colitis or Crohn's disease. It aims to find which treatment is most effective for patients in Upper Egypt.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.